X

HCP Login

By logging in to our website you will have full access to its content, including Healthcare Professional resources. Click here to register or login below.

X

Register your interest

Complete this form to register your interest for this meeting and we will get back to you.

Indicates required fields.

X

Reporting Adverse Events

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. In the Republic of Ireland information can be found at http://www.hpra.ie. Adverse events should also be reported to Merck Serono Limited - Tel: +44(0)20 8818 7373 or email: medinfo.uk@merckgroup.com.

X

Welcome to Merck Neurology

You may request sponsorship to attend a Merck organised meeting. Merck is committed to supporting the professional development and clinical education of healthcare professionals in MS.

Your request for sponsorship will be reviewed by the Merck Medical team. Upon receipt of your request we will email you within a week to advise timelines for the review of your request. Subject to sponsorship being granted, you will be required to sign a sponsorship agreement.

Indicates required fields.

X

Browser Local Storage Cleared

Your local storage for MerckNeurology.co.uk has been cleared. If you continue to use this website we may continue utilise your browsers local storage.

 

Maximum of 20 days of oral dosing in the first 2 years with no further treatment required in the next 2 years1

Click here to view MAVENCLAD® indications and contraindications

 

MAVENCLAD® is the only DMT that can deliver and sustain up to 4 years of disease control with a maximum of 20 days’ oral treatment in the first 2 years1-4

FIND OUT MORE

MAVENCLAD® has low administration and monitoring requirements, while disease control* can be sustained for up to four years1

FIND OUT MORE

MAVENCLAD® has a well-characterised safety and tolerability profile, with over 13 years of clinical study experience in MS1,4,6-8

FIND OUT MORE

MAVENCLAD® is the only oral immune reconstitution therapy (IRT) that selectively
reduces B and T lymphocytes with minimal impact on the innate immune function1,3,9-13

FIND OUT MORE

MAVENCLAD®: Efficacy across all relevant clinical and radiological endpoints†

*Disease control refers to 75.6% of patients who remained relapse-free without further treatment in Years 3 and 435,36
†Vs. placebo including relapse rate, disability progression, MRI activity (T1 Gd+ lesions or active T2-weighted lesions), and NEDA1,2,4,15,16

Supporting your MS patients on their journey with MAVENCLAD

adveva™ is the MAVENCLAD® Patient Support Program. adveva™ is a tailored support service which aims to help patients get the most out of their MAVENCLAD® treatment.

FIND OUT MORE WATCH VIDEO
VIEW REFERENCES

1. MAVENCLAD® Summary of Product Characteristics. Merck.
2. Giovannoni G, et al. N Engl J Med. 2010;362:416–26.
3. Giovannoni G, et al. N Engl J Med. 2010;362:416–26 (Supplementary information).
4. Giovannoni G, et al. Mult Scler. 2018;24:1594–1604.
5. Data on file CLAD005
6. Montalban X, et al. AAN. 2016;[P3.029].
7. Leist TP, et al. Lancet Neurol. 2014;13:257–67.
8. PREMIERE Clinical trials registry. Available at: https://clinicaltrials.gov/ct2/show/NCT01013350 [Accessed 19th November 2018].
9. Baker D, et al. Neurol Neuroimmunol Neuroinflamm. 2017;4:e360.
10. Soelberg-Sørensen P, et al. ENS. 2009;[P359].
11. Soelberg-Sørensen P, et al. ENS. 2010;[P442].
12. Giovannoni G. Neurotherapeutics. 2017;14:874-7.
13. Giovannoni G. Curr Opin Neurol. 2018;31:233–43.
14. Scolding N, et al. Pract Neurol. 2015;15:273–9.
15. Cook S, et al. AAN. 2016;[P3.058].
16. Giovannoni G, et al. Lancet Neurol. 2011;10:329–37.
17. Giovannoni G, et al. Mult Scler. 2018;doi: 10.1177/1352458518771875.
18. Giovannoni G, et al. ECTRIMS. 2017;[P1143].
19. Alemtuzumab Summary of Product Characteristics. Sanofi Genzyme.
20. Natalizumab Summary of Product Characteristics. Biogen.
21. Ocrelizumab Summary of Product Characteristics. Roche.
22. Cook S, et al. EAN. 2017;[P0543].
23. Cook S, et al. Mult Scler. 2011;17:578–93.
24. Cook S, et al. ECTRIMS-ACTRIMS. 2017;[P1142].
25. Galazka A, et al. ECTRIMS-ACTRIMS. 2017;[P1878].
26. MAVENCLAD® European Public Assessment Report, September 2017.
27. Soelberg-Sørensen P, et al. EAN. 2017;[EP3120]
28. Data on File, CLAD001 – Incidence of Lymphopenia, June 2018.
29. Pakpoor J, et al. Neurol Neuroimmunol Neuroinflamm. 2015;2:e158.
30. Stuve O, et al. ECTRIMS. 2017;[P690].
31. Soelberg-Sørensen P, et al. ECTRIMS. 2017;[P1141].
32. Cvetanovich GL, Hafler DA. Curr Opin Immunol. 2010;22:753–60.
33. Ceronie B, et al. J Neurol. 2018;265:1199–1209.
34. Leist TP, et al. Clin Neuropharmacol. 2011;34:28–35.
35. Giovanni G, et al. Mult Scler. 2017; doi:10.1177/1352458517727603.
36. Giovanni G, et al. EAN. 2017; [PO542].
37. Giovanni G, et al. ECTRIMS. 2016.